Printer Friendly

Discovery Laboratories Schedules Year-End Conference Call and Webcast.

Discovery Laboratories, Inc. , a late-stage specialty pharmaceutical company leveraging its technology in humanized lung surfactants to develop novel respiratory therapies, announces a conference call to be held Friday, February 21st at 8:30 AM EST.

Management will review Year-End financial results, and provide an update on its clinical programs including:
 * Current Phase 3 clinical trials for Respiratory Distress Syndrome
 (RDS) in premature infants.
 * Phase 2 clinical trial for Acute Respiratory Distress Syndrome
 (ARDS) in adults including the status of manufacturing activities
 for its surfactant drug product for the ARDS trial at Akorn, Inc.
 * Development of aerosol formulations of its humanized lung surfactant
 technology for broad respiratory disease markets, including the
 collaboration with Aerogen, Inc. to evaluate the delivery of
 Discovery's proprietary humanized lung surfactant with Aerogen's
 aerosol generator technology.

This audio webcast will be available to shareholders and interested parties through a live broadcast on the Internet at and It is recommended that participants log onto one of these sites at least 15 minutes prior to the call. The Internet broadcast will be available for up to 30 days after the call at both website addresses. Interested parties can receive corporate updates by sending their email address to

About Discovery Laboratories, Inc.

Discovery Laboratories, Inc. is a specialty pharmaceutical company leveraging the only platform technology in humanized lung surfactants to develop a number of potential novel respiratory therapies. Surfactants are produced naturally in the lungs and are critical to all air-breathing mammals. Discovery's technology is being developed initially for critical care patients with life-threatening respiratory disorders where there are few or no approved therapies available. Surfaxin(R), Discovery's lead product, is currently in Phase 3 clinical trials for Respiratory Distress Syndrome (RDS) in premature infants, a Phase 3 clinical trial for Meconium Aspiration Syndrome (MAS) in full-term infants, and a Phase 2 clinical trial for Acute Respiratory Distress Syndrome (ARDS) in adults. Aerosol formulations are being developed in an effort to treat a broad range of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), and upper airway diseases such as sinusitis. Discovery is developing a dedicated sales and marketing capability through a collaboration with Quintiles for the United States, and has a strategic alliance with Esteve for Europe and Latin America.
 Company Contact:
 John G. Cooper

 Investor Contact:
 Harvey Goralnick/David Zazoff
 FOCUS Partners LLC

CONTACT: Company Contact: John G. Cooper, SVP, CFO, of Discovery Laboratories, Inc., +1-215-340-4699,; or Investor Contact: Harvey Goralnick or David Zazoff, both of FOCUS Partners LLC, +1-212-752-9445,, for Discovery Laboratories, Inc.

Web site:
COPYRIGHT 2003 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Feb 18, 2003
Previous Article:Hughes Network Systems Provides Broadband Satellite Solution for Amazon Basin Preservation Project; AmazonTech to Expand Brazil's SIVAM...
Next Article:Millennium Bankshares Corporation Announces Fourth Quarter and Year End 2002 Results; * Total Year-End Assets $306.6 million, up 49.2% from prior...

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters